Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 128 versus ISOVUE 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 128 versus ISOVUE 370.
ISOVUE-128 vs ISOVUE-370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast by increasing the density of vascular structures and tissues.
Adult: 50-200 mL (0.5-2.0 mL/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.
Intravenous injection of 50-200 mL of Isovue-370 (iopamidol 76% solution, 370 mg I/mL) for adults, administered as a bolus or infusion depending on imaging protocol. Typical dose for CT: 100-150 mL total volume.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours with GFR <30 mL/min).
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function (creatinine clearance >60 mL/min); prolonged to up to 30 hours in severe renal impairment.
Renal: >95% excreted unchanged in urine via glomerular filtration; fecal/biliary: <5%.
Primarily renal (glomerular filtration) with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% excreted in feces.
Category C
Category C
Contrast Media
Contrast Media